Dossier assessment
Sofosbuvir (hepatitis C in adolescents) - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Sofosbuvir (hepatitis C in adolescents) - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Sofosbuvir (hepatitis C in adolescents) - Benefit assessment according to §35a Social Code Book V
Dossier assessment
Adolescents with genotype 2 or 3 chronic hepatitis C
Pretreated adolescents: hint of a non-quantifiable added benefit; treatment-naïve adolescents: added benefit not proven
Additional information
Federal Joint Committee (G-BA)
2018-04-05 A G-BA decision was published.
Project details
- Project no.
- A17-55
- Commission
- Commission awarded on 12.10.2017 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Immune system and infections
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Connected Projects
-
Dossier assessment
Sofosbuvir (chronic hepatitis C in children) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed